Introduction: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease frequently complicated by diabetic peripheral neuropathy (DPN), which substantially impairs the quality of life and predisposes patients to foot ulceration and amputation. Hypertension, a highly prevalent comorbidity in T2DM, is an important modifiable risk factor for DPN. This review aims to synthesize the current evidence on the association between hypertension and DPN in patients with T2DM and elucidate the underlying pathophysiological mechanisms.
Methods: A narrative literature review was conducted using electronic databases, including PubMed and Google Scholar, to identify clinical, epidemiological, and experimental studies that examined the relationship between blood pressure and DPN in patients with diabetes.
Results: Observational studies across diverse populations consistently demonstrated that coexisting hypertension is associated with a higher prevalence and greater severity of DPN, and multivariate analyses identified hypertension as an independent risk factor after adjusting for age, diabetes duration, and glycemic control. Mechanistically, hypertension acts synergistically with chronic hyperglycemia to aggravate endothelial dysfunction, oxidative stress, inflammation, and structural remodeling of the vasa nervorum, resulting in endoneurial hypoxia, demyelination, and accelerated nerve degeneration. Experimental and imaging studies have corroborated more severe nerve injury when both conditions coexist.
Conclusion: Hypertension is a modifiable contributor to the development and progression of DPN in patients with T2DM. Blood pressure control, alongside glycemic management, should be integrated into DPN prevention strategies, and interventional studies are warranted.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a steadily increasing global prevalence and has become one of the major public health challenges of the 21st century. According to the International Diabetes Federation (IDF), approximately 537 million adults, representing 10.9% of the global adult population, were living with diabetes in 2021, and Indonesia ranked among the five countries with the highest number of people with diabetes [1]. Beyond its metabolic disturbances, T2DM leads to long-term complications that adversely affect quality of life, increase morbidity, and contribute substantially to disability and mortality [2].
In parallel with the rising prevalence of T2DM, chronic complications have become increasingly common, particularly microvascular complications such as diabetic peripheral neuropathy (DPN), diabetic nephropathy, and diabetic retinopathy [3]. DPN is one of the most frequently encountered complications [4]. DPN is a chronic complication characterized by peripheral nerve damage resulting from prolonged hyperglycemia in the absence of other identifiable causes of neuropathy, and it typically presents with tingling, numbness, pain, burning sensations, and sensory loss in the distal extremities in a characteristic “stocking-and-glove” distribution [5]. Pfannkuche et al. reported that approximately 42.2% of patients with T2DM were affected by DPN [6]. DPN substantially impairs quality of life, as neuropathic pain and sensory deficits interfere with daily activities [7]. Moreover, loss of protective sensation in the lower extremities increases the risk of unnoticed injuries, which may progress to diabetic foot ulcers and severe infections [8]. Several factors contribute to the development of DPN, including a longer duration of diabetes, poor glycemic control, advanced age, obesity, dyslipidemia, smoking, and comorbid cardiovascular disease [9]. Chronic exposure to hyperglycemia and dyslipidemia induces metabolic disturbances that activate multiple oxidative stress pathways, ultimately leading to peripheral nerve dysfunction and degeneration [10]. In addition to these factors, hypertension is a highly prevalent comorbidity in patients with diabetes and has been increasingly recognized as a “missed” modifiable risk factor that accelerates the development of DPN [11]. Elevated blood pressure contributes to microvascular damage by increasing pressure within the small vessels supplying peripheral nerves, thereby reducing endoneurial blood flow and tissue oxygenation and impairing glucose metabolism within neural tissue [12].
In patients with diabetes, the coexistence of hypertension further increases the risk of DPN through synergistic effects of chronic hyperglycemia and elevated blood pressure on oxidative stress, inflammation, and endothelial dysfunction. Consequently, hypertension should be regarded not merely as a common comorbidity but as an independent contributor to the onset and progression of DPN [11]. Although several studies have demonstrated a significant association between hypertension and DPN in patients with T2DM, hypertension remains underemphasized in routine DPN prevention compared with glycemic control. Therefore, this narrative review aims to synthesize current evidence on the role of hypertension in the development of DPN in patients with T2DM and to elucidate the underlying mechanisms of peripheral nerve injury in this setting.
This review searched PubMed and Google Scholar for publications on hypertension, T2DM, and DPN. Terms included “type 2 diabetes mellitus,” “diabetic peripheral neuropathy,” “diabetic neuropathy,” “hypertension,” “blood pressure,” and “risk factor.” Included original articles (cross-sectional, case–control, and cohort studies), animal studies, systematic and narrative reviews, and guidelines in English or Indonesian. Studies selected for epidemiology, risk factors, and pathophysiological mechanisms linking hypertension and DPN. Findings were synthesized thematically.
T2DM is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from reduced tissue responsiveness to insulin (insulin resistance), which may eventually lead to impaired pancreatic β-cell function and inadequate insulin secretion [13]. As the disease progresses, chronic hyperglycemia gradually damages multiple organ systems through injury to the microvasculature, leading to microvascular complications, including diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy [3].
DPN is one of the most common long-term complications of diabetes and is characterized by damage to the peripheral nervous system as a consequence of chronic hyperglycemia, which induces progressive injury to peripheral nerve fibers. Clinically, DPN may present with sensory disturbances (numbness, tingling, and neuropathic pain), motor dysfunction (muscle weakness and impaired coordination), and autonomic abnormalities [14]. Distal symmetric polyneuropathy is the most common clinical subtype [5].
DPN is among the most prevalent complications in individuals with T2DM, and it is estimated that approximately 50%–66% of individuals with diabetes will develop DPN during their lifetime. Although neuropathy may occur in all types of diabetes, its prevalence is generally higher in T2DM, and the risk increases with longer disease duration and the presence of comorbidities [2]. In Indonesia, the reported prevalence of DPN among patients with T2DM ranges from 30% to 50% [15].
Chronic hyperglycemia initiates multiple interconnected pathophysiological mechanisms that contribute to DPN. Activation of the polyol pathway increases the conversion of glucose to sorbitol, resulting in the depletion of nicotinamide adenine dinucleotide phosphate (NADPH). This reduces cellular antioxidant capacity and generates oxidative stress that damages both neurons and the microvasculature supplying peripheral nerves. Oxidative stress is further amplified by activation of the hexosamine pathway and the formation of advanced glycation end products (AGEs), which promote inflammation and neuronal injury [16-18].
In addition, chronic hyperglycemia induces microvascular alterations, including thickening of the vascular basement membrane, endothelial dysfunction, and impaired regulation of vasodilation and vasoconstriction. These changes reduce nerve perfusion, resulting in endoneurial hypoxia and ischemia. Neural injury is accompanied by altered ion channel expression, neuronal hyperexcitability, and abnormal nerve fiber sprouting, which enhance pain signal transmission. Persistent nociceptive input eventually leads to central sensitization through increased glutamatergic activity and N-methyl-D-aspartate (NMDA) receptor activation, along with reduced γ-aminobutyric acid (GABA)-mediated inhibition within the central nervous system. Collectively, these mechanisms give rise to the clinical manifestations of neuropathic pain, including burning sensations, tingling, electric shock-like pain, diminished pain and temperature sensation, and motor weakness [19].
Patients with DPN commonly present with tingling, numbness, burning sensation, pain, and/or muscle weakness. These symptoms typically begin in the feet and progress proximally in a length-dependent “stocking-and-glove” pattern. Manifestations are usually symmetrical, with sensory deficits predominating over motor impairments. Some patients experience numbness while simultaneously exhibiting heightened sensitivity to normally nonpainful stimuli, a phenomenon known as allodynia. In severe cases, DPN leads to chronic, non-healing foot ulcers; approximately 15% of patients develop foot ulceration during the course of the disease, and a substantial proportion eventually require lower limb amputation [19].
In addition to distal symmetric polyneuropathy, patients with T2DM may develop other forms of neuropathy. Small-fiber neuropathy is often an early manifestation and may remain asymptomatic and undetected in its initial stages. Autonomic neuropathy may present with urinary dysfunction, gastrointestinal symptoms, erectile dysfunction, heat intolerance, dysphagia, cardiac arrhythmias, orthostatic hypotension, and syncope. Diabetic radiculoplexus neuropathy involves the major nerve plexuses and is characterized by pain, muscle weakness, and impaired balance, whereas mononeuropathy affects a single peripheral nerve, such as the median or peroneal nerve, with manifestations depending on the nerve involved [14].
The development of DPN in T2DM is influenced by multiple interacting risk factors, which may be classified as modifiable or non-modifiable. Modifiable risk factors include hypertension, dyslipidemia, smoking, poor glycemic control, being overweight or obese, and excessive alcohol consumption, whereas non-modifiable risk factors include older age, longer duration of diabetes, and genetic predisposition [12].
A longer duration of diabetes increases the risk of DPN due to prolonged exposure to chronic hyperglycemia. Rahmi et al. reported a significant correlation between the duration of T2DM and the occurrence of DPN [20]. Similarly, Liu et al. demonstrated that compared with patients with diabetes for less than 5 years, those with a disease duration of 10–15 years had a significantly higher risk of DPN (OR = 1.629; 95% CI: 1.261–2.106; p < 0.001), with the risk increasing further among those with a duration of ≥15 years (OR = 1.898; 95% CI: 1.483–2.429; p < 0.001) [21].
Hypertension is defined as persistently elevated systolic blood pressure (SBP) of ≥140 mmHg and/or diastolic blood pressure (DBP) of ≥90 mmHg [22]. Based on etiology, hypertension is classified as primary (essential) or secondary. Primary hypertension accounts for approximately 80%–95% of cases and results from complex interactions between genetic and environmental factors, whereas secondary hypertension arises from identifiable underlying conditions, such as renal or endocrine disorders. Because hypertension is frequently asymptomatic, many individuals remain undiagnosed until elevated blood pressure is detected during routine evaluation [23].
Hypertension is one of the most common comorbidities in patients with T2DM, and the two conditions frequently coexist and synergistically drive both micro-and macrovascular complications. Naseri et al. reported that hypertension was present in 70.5% of patients with T2DM, with a higher prevalence among women than men [24]. whereas Al-Hadi et al. found hypertension in 46.8% of patients with T2DM in an Indonesian hospital setting [25]. Globally, the prevalence of hypertension among individuals with T2DM is estimated to be 50%–80%, and patients who are hypertensive at the time of diabetes diagnosis exhibit higher mortality and an increased risk of cardiovascular complications compared with normotensive patients [26].
Table 1. Summary of key clinical and experimental studies evaluating the association between hypertension and
diabetic peripheral neuropathy (DPN).
| Study | Design / population | Key findings |
| Jarmuzewska et al., 2007 [34] | Clinical study; patients with T2DM | Hypertension independently associated with sensorimotor neuropathy after multivariable adjustment (R² = 0.17, p = 0.023) |
| Sanada et al., 2015 [32] | Experimental animal model; sural nerve morphometry | Combined hypertension and diabetes produced more severe axonal atrophy, demyelination, small-fiber loss, and microvascular abnormalities |
| Rahmawati et al., 2018 [29] | Cross-sectional; patients with T2DM, Indonesia | History of hypertension significantly associated with DPN (p = 0.03) |
| Esmat et al., 2022 [27] | High-resolution ultrasound of the median nerve; hypertensive patients with and without diabetes | Higher neuropathy prevalence in hypertension plus diabetes vs. diabetes alone (34% vs. 22%) |
| Hasyim et al., 2023 [30] | Observational; outpatients with T2DM, Indonesia | Significant relationship between hypertension and DPN (p = 0.001) |
| Asram et al., 2024 [28] | Case–control; 124 patients with diabetes, Indonesia | Significant association between hypertension and DPN (p = 0.0011) |
| Gebreziher et al., 2024 [33] | Multicenter cross-sectional; patients with T2DM, Ethiopia | 69.6% had hypertension >5 years; neuropathy frequently observed in this group |
DPN, diabetic peripheral neuropathy; T2DM, type 2 diabetes mellitus.
Hypertension may influence the development of DPN through mechanisms involving microvascular injury [26]. Elevated blood pressure induces microvascular dysfunction, impairing the microcirculation that supplies oxygen and nutrients to peripheral nerves, reducing nerve conduction and compromising axonal integrity [27]. Clinical and experimental studies investigating this relationship are summarized in Table 1. In a case–control study of 124 patients with diabetes, Asram et al. demonstrated a significant association between hypertension and DPN in T2DM (p = 0.0011) [28]. These findings are consistent with those of a cross-sectional study by Rahmawati et al., which identified a history of hypertension as significantly associated with DPN (p = 0.03) [29]. and with those of Hasyim et al., who reported a significant relationship between hypertension and DPN in T2DM (p = 0.001) [30].
Using high-resolution ultrasound, Esmat et al. demonstrated that patients with both hypertension and diabetes exhibited a moderate positive correlation between the vibration perception threshold and median nerve parameters (r = 0.39, p = 0.005), indicating a significant relationship between functional and structural nerve impairment. The study also reported a higher prevalence of neuropathy in patients with coexisting hypertension and diabetes than in those with diabetes alone (34% vs. 22%), suggesting that this combination accelerates peripheral nerve damage [27]. In a narrative review, Bondar et al. identified hypertension as an independent risk factor for DPN, attributable to impaired impulse conduction secondary to myelin sheath thinning accompanied by compensatory Schwann cell activation [31]. Consistently, a systematic review concluded that hypertension is a consistent, yet frequently overlooked, modifiable risk factor for diabetic neuropathy [11]. Beyond elevated blood pressure per se, prolonged hypertension contributes to peripheral neuropathy through chronic microvascular injury and nerve ischemia, and these effects appear to be synergistic with chronic hyperglycemia. Sanada et al. investigated this interaction in an experimental animal model comprising control, hypertension, diabetes, and combined hypertension and diabetes groups. Histopathological and morphometric analyses of the sural nerve have demonstrated that the combination of hypertension and diabetes produces more severe nerve damage, including axonal atrophy, demyelination, loss of small nerve fibers, and microvascular abnormalities [32]. In a multicenter study from Ethiopia, Gebreziher et al. reported that 69.6% of patients with T2DM had a history of hypertension lasting more than five years and that diabetic neuropathy was frequently observed in this group, suggesting a potential relationship between hypertension duration and DPN [33]. Furthermore, Jarmuzewska et al. demonstrated that hypertension remained independently associated with sensorimotor peripheral neuropathy in T2DM after adjusting for age, sex, diabetes duration, HbA1c, and serum cholesterol (R² = 0.17, p = 0.023) [34].
The mechanisms linking hypertension to DPN have not been fully elucidated. Chronic hyperglycemia initiates multiple pathways that promote oxidative stress and endothelial dysfunction, leading to increased arterial stiffness, progressive microvascular injury, and hypertension further amplifies these deleterious effects. Reduced Na⁺/K⁺-ATPase activity has been reported in hypertensive states, which may aggravate hyperglycemia-induced polyol pathway dysfunction [11]. Patients with diabetes also exhibit impaired myogenic tone and vascular hypertrophy, resulting in narrowing of the microvascular lumen; these alterations compromise endoneurial blood flow and contribute to progressive nerve injury [35]. Reduced luminal diameter may additionally impair nutrient and glucose transport, further disrupting neural glucose homeostasis [29]. Moreover, the loss of unmyelinated small nerve fibers in the skin has been shown to progress more rapidly under hypertensive conditions [36].
Inflammation provides a link. Putri et al. found that poor glycemic control, reflected by elevated HbA1c, was linked to increased inflammation, indicated by higher hs-CRP concentrations, and that systolic blood pressure correlated positively with hs-CRP in patients with T2DM (r = 0.277, p = 0.044) [37]. Therefore, hypertension may exacerbate endothelial dysfunction and accelerate microvascular injury through inflammatory pathways; consistently, higher blood pressure is associated with severe neuropathic symptoms in patients with T2DM [38].
These findings have important implications for clinical practice. Because hypertension is a modifiable risk factor, systematic blood pressure control should be regarded as an integral component of DPN prevention, alongside glycemic management, rather than solely as a cardiovascular intervention [11]. Experimental data further suggest that therapy targeting the renin–angiotensin system, as part of combination treatment, may improve neuropathy-related endpoints in diabetic models [36]. In practice, patients with T2DM and coexisting hypertension should be regarded as a high-risk group warranting regular neuropathy screening and structured foot care education to prevent ulceration and amputation [8].
Several limitations of the available evidence must be acknowledged. Most clinical studies are cross-sectional or case–control in design, precluding causal inference, and many were conducted in single centers with modest sample sizes. The definitions of hypertension and DPN, as well as the diagnostic methods for neuropathy, vary considerably across studies, limiting comparability. Furthermore, important confounders such as antihypertensive drug classes, blood pressure variability, and the duration of hypertension have been inconsistently reported. Large prospective cohorts and randomized trials are needed to evaluate specific blood pressure targets and antihypertensive classes for DPN prevention.
DPN, a T2DM complication, impairs quality of life. Hypertension, a modifiable factor, is independently associated with DPN occurrence and severity. This involves microvascular damage, endothelial dysfunction, inflammation, and perfusion and oxygen delivery, synergizing with chronic hyperglycemia to accelerate nerve degeneration. Blood pressure control, glycemic management, and neuropathy screening should be integrated into care.
None
The Authors agree to be published in the Journal of Society Medicine.
None
The authors declare no conflicts of interest in this case report.
W. Z. D. contributed to the conceptualization of the review, literature search, data extraction and synthesis, and drafting of the manuscript. Y. I. contributed to the conceptualization, supervision, critical interpretation of the evidence, and critical revision of the manuscript for important intellectual content. Both authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.
The authors gratefully acknowledge the Faculty of Medicine, Universitas Trisakti, Jakarta, and the Department of Neurology for their academic support and access to scientific resources that made this review possible.